Sermorelin is a biologically active analogue of growth hormone-releasing hormone (GHRH), which is produced by the human brain to promote the production and release of growth hormone from the pituitary gland. It encourages the body to produce its own human growth hormone (HGH). Sermorelin is a shorter version of the growth hormone-releasing factor (GRF 1-44) that the brain naturally generates to stimulate the pituitary's production and secretion of HGH. In youth, the body generates sufficient amounts of GHRH, enabling the pituitary gland to supply enough growth hormone for maintaining health, vitality, and normal bodily function. As a person ages, GHRH levels decrease, resulting in reduced HGH production and secretion from the pituitary, which contributes to the effects of growth hormone deficiency.
Unlike HGH, Sermorelin targets a more fundamental source of dysfunction within the GH neuroendocrine axis, exhibits greater physiological activity, boasts a superior safety profile, and is not limited in use for adult hormone deficiency. While Sermorelin yields similar effects on body composition and offers the associated benefits of HGH, it also presents additional significant advantages. The impact of Sermorelin is regulated by negative feedback at the pituitary gland level and the release of somatostatin, which minimizes or eliminates safety concerns related to HGH overdose. The release of HGH from the pituitary due to Sermorelin action is episodic rather than "square wave," thus preventing tachyphylaxis by mimicking normal physiological patterns. By stimulating the pituitary, it preserves more of the growth hormone neuroendocrine axis that typically fails first with aging.